Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Aptus Capital Advisors LLC

Aptus Capital Advisors LLC raised its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 29.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 339,750 shares of the biopharmaceutical company's stock after buying an additional 76,940 shares during the period. Aptus Capital Advisors LLC owned approximately 0.22% of Ocular Therapeutix worth $2,901,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of OCUL. Barclays PLC raised its holdings in shares of Ocular Therapeutix by 37.1% during the third quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock valued at $4,451,000 after buying an additional 138,441 shares during the last quarter. Courier Capital LLC acquired a new position in Ocular Therapeutix during the fourth quarter worth $482,000. RoundAngle Advisors LLC bought a new position in shares of Ocular Therapeutix in the fourth quarter valued at approximately $1,695,000. SG Americas Securities LLC grew its position in shares of Ocular Therapeutix by 58.7% in the fourth quarter. SG Americas Securities LLC now owns 71,698 shares of the biopharmaceutical company's stock valued at $612,000 after purchasing an additional 26,511 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Ocular Therapeutix by 11.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company's stock worth $285,000 after buying an additional 3,347 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Ocular Therapeutix Stock Performance

Shares of NASDAQ OCUL traded down $0.13 during trading on Wednesday, reaching $7.05. 1,985,608 shares of the company traded hands, compared to its average volume of 1,428,752. The stock has a market capitalization of $1.12 billion, a PE ratio of -5.34 and a beta of 1.51. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. Ocular Therapeutix, Inc. has a 52-week low of $4.79 and a 52-week high of $11.78. The firm has a 50 day simple moving average of $7.42 and a 200-day simple moving average of $8.35.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The business had revenue of $17.08 million for the quarter, compared to the consensus estimate of $16.89 million. Equities research analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,475 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the sale, the insider now owns 3,520,318 shares in the company, valued at $24,184,584.66. This represents a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 3.50% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. William Blair assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. They set an "outperform" rating for the company. Royal Bank of Canada started coverage on Ocular Therapeutix in a report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 target price on the stock. Needham & Company LLC reduced their price objective on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday. JMP Securities set a $19.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Finally, HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $16.25.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.